Discovery of MFH290: A Potent and Highly Selective Covalent Inhibitor for Cyclin-Dependent Kinase 12/13
- 9 July 2020
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 63 (13), 6708-6726
- https://doi.org/10.1021/acs.jmedchem.9b01929
Abstract
Genetic depletion of cyclin-dependent kinase 12 (CDK12) or selective inhibition of an analog-sensitive CDK12 reduces DNA damage repair gene expression, but selective inhibition of endogenous CDK12 is difficult. Here, we report the development of MFH290, a novel cysteine (Cys)-directed covalent inhibitor of CDK12/13. MFH290 forms a covalent bond with Cys-1039 of CDK12, exhibits excellent kinome selectivity, inhibits the phosphorylation of serine-2 in the C-terminal domain (CTD) of RNA-polymerase II (Pol II), and reduces the expression of key DNA damage repair genes. Importantly, these effects were demonstrated to be CDK12-dependent as mutation of Cys-1039 rendered the kinase refractory to MFH290 and restored Pol II CTD phosphorylation and DNA damage repair gene expression. Consistent with its effect on DNA damage repair gene expression, MFH290 augments the antiproliferative effect of the PARP inhibitor olaparib.Funding Information
- Foundation for the National Institutes of Health (1RO1 CA179483-01A1)
- Dana-Farber Cancer Institute (Dana-Farber Cancer Institute Accelerator Grant, Susan Smith Center for Women???s Cancer- PPG Award)
This publication has 27 references indexed in Scilit:
- CDK12 Inhibition Reverses De Novo and Acquired PARP Inhibitor Resistance in BRCA Wild-Type and Mutated Models of Triple-Negative Breast CancerCell Reports, 2016
- Covalent targeting of remote cysteine residues to develop CDK12 and CDK13 inhibitorsNature Chemical Biology, 2016
- Non-canonical functions of cell cycle cyclins and cyclin-dependent kinasesNature Reviews Molecular Cell Biology, 2016
- Engineering an analog-sensitive CDK12 cell line using CRISPR/CasBiochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms, 2015
- The history and future of targeting cyclin-dependent kinases in cancer therapyNature Reviews Drug Discovery, 2015
- Targeting transcription regulation in cancer with a covalent CDK7 inhibitorNature, 2014
- Ovarian Cancer-associated Mutations Disable Catalytic Activity of CDK12, a Kinase That Promotes Homologous Recombination Repair and Resistance to Cisplatin and Poly(ADP-ribose) Polymerase InhibitorsOnline Journal of Public Health Informatics, 2014
- Genome-wide Profiling of Genetic Synthetic Lethality Identifies CDK12 as a Novel Determinant of PARP1/2 Inhibitor SensitivityCancer Research, 2014
- Interaction of Cyclin-Dependent Kinase 12/CrkRS with Cyclin K1 Is Required for the Phosphorylation of the C-Terminal Domain of RNA Polymerase IIMolecular and Cellular Biology, 2012
- Cell cycle, CDKs and cancer: a changing paradigmNature Reviews Cancer, 2009